

**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT
DIABETES**
(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 11
Independent Auditor's Report on the Financial Statements	12 - 15
Statement of Financial Activities	16
Balance Sheet	17 - 18
Statement of Cash Flows	19
Notes to the Financial Statements	20 - 36

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2024

Trustees	Professor David Maahs, President Dr Jannet Svensson (appointed 19 October 2024) Dr Jamie Wood, Secretary General Dr Sabine Hofer Dr Fergus Cameron (appointed 19 October 2024)
Company registered number	06641016
Charity registered number	1126927
Registered office	Ellenborough House Wellington Street Cheltenham Gloucestershire GL50 1YD
Management Company / Principal Office	K.I.T. Group GmbH
Company secretary	Dr Jamie Wood
Independent auditor	Wilkes Tranter & Co Limited Chartered Accountants Statutory Auditors Brook House Moss Grove Kingsinford West Midlands DY6 9HS
Bankers	Commerzbank Berlin-Gedächtniskirche Kurfürstendamm 237 10719 Berlin Germany Lloyds Bank Plc Rotunda Montpellier Cheltenham Gloucestershire GL50 1SH

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees under Charity Law, who are also the Directors under Company Law, present their report and the financial statements of the Charity for the period ended 31 December 2024. This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The International Society for Paediatric and Adolescent Diabetes - ISPAD - is a charitable company, limited by guarantee, incorporated on 8 July 2008 (registration number 06641016) and registered as a charity on 25 November 2008 (charity number 1126927).

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

The International Society for Paediatric and Adolescent Diabetes (ISPAD or the Society) is governed by its Memorandum and Articles of Association dated 8 July 2008 (last amended 13 June 2023); and the UK Charity Governance Code.

Principal Activity

ISPADs Overall mission is to bring together professionals from various disciplines with an interest in clinical care, science, education, and advocacy to prevent, treat or cure all forms of diabetes in youth by promoting networking and collaboration. The principal activity of ISPAD is to improve the lives of children, adolescents and young adults with diabetes worldwide, which is accomplished by providing forums, both written (guidelines) and face-to-face (scientific meetings, science schools for physicians and for allied healthcare professionals, and postgraduate courses), to physicians and healthcare professionals who provide care for young people with diabetes. To advance these aims further, ISPAD advocates throughout the world for the appropriate provision of medical care and assists international organisations and health services in the delivery of educational and promotional material for all children and adolescents with diabetes.

Organisational Management

Each officer of the Charity has a role and responsibilities that are enumerated in the governing document. The Society's focus on Science, Advocacy and Education is ensured by the officers of the Society who serve as Trustees. They have the ultimate responsibility for fiscal and other decisions in accordance with the Memorandum and Articles of Association, and any bylaws. They consult with the advisory council composed of members of the Society elected each year at the Annual Conference. Advisory council members are specifically sought from different regions of the world so that they are representative of the membership as a whole. The advisory council formally meets with the board twice each year. Between meetings information is exchanged by e-mail and regular conference calls. The dissemination of information on important issues does not need to wait for formal meetings.

The Trustees retain an organisational management group (K.I.T. Group GmbH, Berlin, Germany) who deal with the day-to-day activities of the Society and advises the Trustees in this regard. They have the ability to allocate their employees in any manner that best serves the Society and are granted a license to organise and manage the Annual Conference, the venue for which is selected by the Executive Board. K.I.T. Group reviews the locations, budgets and logistics for the Society and signs the contracts between the management group and venues and exhibitors. K.I.T. Group also collaborates with and provides logistical support to the local conveners and international Scientific Committee, which creates the scientific program and selects speakers.

The management group maintains for the Society records of day-to-day financial transactions and provides reports to the Treasurer and other Trustees at regular intervals. K.I.T. Group processes receipts and transfers funds from the Society's accounts (used for day-to-day activities) with the approval of the Treasurer, or the Trustees as a whole, during Trustee meetings or after discussions with Trustees. They organise the venue and related activities for Directors' meetings. The Charity retains both an accounting firm and solicitors. These advise the Trustees on governance, legal, and financial issues.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Recruitment and Training of Trustees

The Trustees of the Society are the current serving officers of the Society. The Trustees are elected by the members at the Annual Conference. The processes for nomination and election of the Trustees are outlined in the Articles and Memorandum (amended 12 October 2012 to allow electronic voting). Trustees have been members of the Society for many years and have contributed to the Society in many areas; e.g. serving on the Advisory Council, organising one or more of the Annual Scientific meetings, science schools or postgraduate courses. Trustees have contributed to the Society's efforts in Science, Education and Advocacy, which are the pillars of the Society.

Newly elected Trustees spend one year as Trustee-elect and attend the Board/Trustee meetings to gain experience in the Society's activities: charity governance, finances, grant processing/approvals and other issues involving the organisation and running of the Society. Trustees must be members in good standing of the Society and have participated in the Society's activities in leadership roles. They receive formal information about the role and responsibilities of a Trustee, and undertake self-paced learning from documents available through the Charity Commission. The year spent serving as Trustee-elect allows on the job experience, guidance and education from the current Trustees prior to assuming the responsibility of a Trustee.

Structure and Relationships

The Trustees/Board of Directors communicate with each other (usually via email) almost daily on the management and direction of the Charity. A regular formal video conference meeting is arranged monthly between the Officers and the Administration Company.

The Trustees retain an organisational management group to assist with the actual day-to-day management of the Charity and the Board has direct oversight of their activities. The Society contracts with the management group to organise and manage the Annual Conference. The management group also provide material support for meetings, organises the Annual Report with the Trustees, which is prepared for distribution at the Annual General Meeting (and available for consultation in the member area on the ISPAD website) and provides a postconference report for the Trustees after the Annual Conference.

Formal management reports are presented to the Trustees at face-to-face meetings at least twice per year. A written report is presented to the Trustees and members at the Annual General Meeting. Information is exchanged by e-mail or telephone frequently on an 'as needed' basis. Financial reports are given to the Treasurer regularly, and the Trustees are updated regularly.

The Trustees, on behalf of the Society, worked on new journal partnership opportunities and established in June 2024 a contract with Karger, as the new publisher of the Society's journal, Hormone Research in Paediatrics, to provide subscriptions to the journal to all ISPAD members. Subscription to the Journal Hormone Research in Paediatrics published by Karger is provided for all ISPAD members. Members have full online access, they will be nominated to the Editorial Board of the journal, the ISPAD Guidelines and other society reports will be published in the journal.

The Society has established agreements of cooperation, collaboration and Memoranda of Understanding with other Charities, companies and Medical Professional Organisations with similar objectives and aims on a need's basis.

The Trustees contract for facility space, audio-visual supplies and support, and food for the Winter administration meeting (usually held during the international conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Europe) and the Summer meeting usually held during the American Diabetes Association Annual Scientific Meeting (ADA) in the United States of America.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees set policies and guidelines for organising and running the Annual Conference. The Trustees, on behalf of the Society, provide scientific oversight and work closely with the conveners and international scientific committee on the program of the Annual Conference.

Risk Management

The Trustees of ISPAD are committed to the Society's mission and have joined its board because they want to help the charity most effectively carry out its mission for the benefit of children, adolescents, young people and families with diabetes. Trustees fully recognize that meeting their charity's stated public benefit is an ongoing requirement, understand their roles and legal responsibilities, and are committed to good governance, and wish to contribute to ISPAD's continued improvement.

The board acts with integrity, adopting values and creating a culture that helps achieve the organisation's charitable purposes. The board is aware of the importance of the public's confidence and trust in charities, and trustees undertake their duties accordingly.

Trustees have the ultimate fiduciary responsibility for managing ISPAD's funds and assets, protecting its reputation, and maintaining the respect of beneficiaries, other stakeholders and the public by behaving with integrity at all times, even when difficult or unpopular decisions are required.

The board leads the organisation in being transparent and accountable. The charity is open in its work, unless there is good reason for it not to be. The public's trust that a charity is delivering a public benefit is fundamental to its reputation and success. Making accountability real, through genuine and open two-way communication that celebrates successes and demonstrates willingness to learn from mistakes, helps to build this trust and confidence and earn legitimacy.

OUR VISION, MISSION, AND VALUES

Our Vision

A better world for children, adolescents and young adults with diabetes.

Mission Statement

To bring together professionals from various disciplines with an interest in clinical care, science, education and advocacy to prevent, treat or cure all forms of diabetes in youth.

By promoting networking and collaboration, our aims are:

- To ensure appropriate treatment is available, including medication, self-monitoring equipment and supplies;
- To increase awareness of all types of diabetes and prevent delayed diagnosis;
- To reduce the morbidity and mortality caused by acute and chronic complications;
- To ensure provision of education to youth, families and other caregivers;
- To promote education of diabetes healthcare teams worldwide;
- To foster diabetes research; and
- To prepare and disseminate clinical practice guidelines and standards.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Our Values

Excellence

In care, based on rigorous and ethical research with respect for the individual child, adolescent and family and by creating, evaluating and disseminating diabetes knowledge.

Collaboration

The Society collaborates with national and international patient and professional organisations, healthcare providers, policy makers and companies that make products or provide services for children with diabetes.

Advocacy

For children and caregivers to improve awareness that diabetes is different for children compared to adults; to end discrimination based on a child's diabetes; and to obtain increased funding for diabetes treatment, research and prevention.

- To promote the care of children and adolescents with all forms of diabetes mellitus;
- To be an advocate for children and adolescents with all forms of diabetes mellitus; and
- To encourage and support basic, clinical, epidemiological, health, economic and all other relevant research concerning paediatric and adolescent diabetes mellitus.

Public Benefit

Please see below a summary of the principal activities and accomplishments for the year which ISPAD has carried out for the public benefit.

In the furtherance of these objectives, the ISPAD Trustees have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to the Charity Commission's published general and relevant sub-sector guidance concerning the operation of the Public Benefit requirement under that Act.

PRINCIPAL ACTIVITIES AND ACCOMPLISHMENTS

Education

The extensive Clinical Practice Consensus Guidelines (26 chapters), published in 2022, continue to be promulgated and made available on the Society's website and published in Pediatric Diabetes, the Society's former journal. The Clinical Practice Consensus Guidelines are an up-to-date reference for all those concerned with the management of childhood diabetes worldwide and include guidelines for under resourced areas. The Guidelines were developed and written by members of the Society, led by an editorial team. This last comprehensive revision consists of 26 chapters and over 250 authors (global distribution, early career and senior, diverse professional background, and persons with diabetes). In addition, an external project officer was appointed to take a lead in supporting the editorial team to ensure the guidelines meet international standards for clinical guidelines and ensure harmonisation of recommendations, content, language and evidence grading across chapters.

The Guidelines are evidence-based and are written using a review process involving input from the entire membership, led by our excellent and enthusiastic volunteer editorial team. A copy of each chapter is available for download by anyone (not only for the members) at no cost from our website www.ispad.org. ISPAD has been collaborating with partners on the translation of the ISPAD 2022 Guidelines into various languages to facilitate even broader access. By today, the Guidelines are available English, French, Spanish, Portuguese and Hindi. In addition, translations into other languages are encouraged with no charge from ISPAD who coordinates these efforts to avoid redundant translations.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

ISPAD's Clinical Practice Consensus Guidelines are the only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes worldwide! As some chapters are subject to a rapid turn-over and require an early update, six chapters of ISPAD's Clinical Practice Consensus Guidelines were revised and updated accordingly in 2024.

The chapters from the ISPAD Clinical Practice Consensus Guidelines 2024 set that has been published in ISPAD's official Journal (Hormone Research in Paediatrics) are listed below (six chapters and one editorial):

- Chapter 02: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes
- Chapter 03: Type 2 Diabetes in Children and Adolescents
- Chapter 08: Glycemic Targets
- Chapter 09: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes
- Chapter 16: Diabetes Technologies: Insulin Delivery
- Chapter 17: Diabetes Technologies: Glucose Monitoring
- ISPAD Clinical Practice Guidelines 2024: Editorial

Educational courses are offered to the membership both, in virtual format (Webinars, online learning tools) and in person Annual Conference, Science School for Physicians and Science School for Healthcare Professionals, as well as Postgraduate Courses.

Advocacy

ISPAD collaborates closely with 'Life for a Child' and 'Changing Diabetes in Children' two major programs whose aim is to improve access to essential diabetes medicines (insulin) and supplies for children in the developing world. ISPAD also collaborates with 'Action4Diabetes', a charity providing health to disadvantaged young people with Diabetes in South-East Asia. ISPAD also collaborates with organisations providing help in areas hit by humanitarian crisis – 'International Alliance for Diabetes Action (IADA)' – to support them with guidelines needed to deal with persons suffering from diabetes in areas without regular diabetes care and supply due to humanitarian crisis.

ISPAD is a society that opened its membership for advocates and offers a separate membership for advocates.

Science

The Annual Conferences involve presentation of research activities, state-of-the-art lectures and topic specific symposia. In 2020 and 2021, ISPAD's Annual Conference took place virtually over a three-day meeting in October 2020 and 2021 with 1,285 and 1,414 participants respectively. In 2022, the Annual Conference was held in person in Abu Dhabi, United Arab Emirates October 13-16. In total, the meeting brought together 1058 attendees (781 face-to-face, 277 virtual), and 369 scientific abstracts were submitted. In 2003, the Annual Conference was held in Rotterdam, Netherlands with a total of 1,623 Attendees from 100 countries and 489 abstracts submitted by authors from all parts of the world. In 2024, the Annual Conference was held in Lisbon, Portugal with a total of 1,830 delegates attendees from 83 countries and 636 abstracts submitted by authors from all parts of the world. The attendance in 2024 has been the best ever. At the meeting in Lisbon the organisation celebrated its 50th anniversary, showing the long standing need for the society as such and the success throughout all those years.

ISPAD organises and runs, with volunteer experts, an annual research-oriented Science School for Physicians (held in person in Pittsburgh, Pennsylvania, USA in September 2024), as well as a Science School for Allied Healthcare Professionals working in diabetes (held in person in Lisbon, Portugal in October 2024). Applications are very competitive for both science schools each year and include participants from all over the world.

Visiting Fellowships allow young physicians and healthcare professionals to study research techniques and prepare them to set up research proposals, either in collaboration with the centre in which they study, or to initiate research in a similar area in a more independent manner by providing hands-on experience in an established Centre of Excellence of research in the domain of interest. Applicants present a research proposal

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

for their study as well as references, with letters of support from their hospital or university and from the head of the research centre to which they are applying (directed by an ISPAD member) attesting to the applicant's acceptance at the centre to pursue the research project as presented. The accepting ISPAD member volunteers their time and centre resources for the project. The funds allow the recipient to travel to the centre and provide support for accommodation.

Since 2017 ISPAD collaborates with Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation (JDRF)) and from 2024 onwards, the funding of the Research Fellowship increases to 25,000-40,000 dollars range to fund up to 11 fellows, and since the calendar year 2019, 10 Allan Drash fellowships, of 7,500 dollars each. The applications are reviewed by the Trustees and the Advisory Committee who rank them on the quality of the application and potential benefits to the applicant. The successful recipient provides ISPAD with a report on the project and is encouraged to submit an abstract to the Annual Conference and/or submit a manuscript to the ISPAD Journal.

Grants from General Funds

Travel grants are for young physicians and healthcare professionals whose abstracts have been accepted for presentation at the Annual Conference. ISPAD support travel grants (scaled according to geographical location) and special travel grants (full payment of travel, registration and accommodation for members from the developing world).

The abstract quality (scoring as per reviewing process by the Abstract Committee) as well as the country of residence and profession were part of the selection criteria for allocating these grants. Applications from Lower Income Countries (as per World Bank classification) and Allied Healthcare Professionals were explicitly encouraged.

Grants Supported by Funds from Restricted Grants

Grants were obtained for the Science School for Physicians for a 5-day course for 19 young physician scientists in 2024 to learn how to design a research study, apply proper statistics and write grants. These grants were provided in 2024 by Breakthrough T1 D (formerly JDRF).

Volunteers

Members of the Society participate in all aspects of the Society e.g.:

- serving on the Advisory Council
- serving as convener and organising committee members for the Annual Conference
- serving on the Scientific Committee
- reviewing abstracts for the Annual Conference
- acting as faculty for the Science Schools and post graduate courses
- serving on writing committees for the Clinical Practice Guidelines
- serving on special interest group
- advocating for children with diabetes at local, regional and international levels
- working with sponsors to increase contributions
- attending the Annual Conference (primary fund-raising event)
- serving as preceptors for Visiting Fellows
- providing leadership in diabetes care for children and adolescents locally.

Members

The International Society for Paediatric and Adolescent Diabetes has members from more than 100 countries. A membership directory can be found on the ISPAD website (www.ispad.org).

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

FINANCIAL REVIEW AND RESULTS FOR THE PERIOD

Financial Review

The current period is for the 12 month-period ended 31 December 2024 ('2024'). The prior period is for the year ended 31 December 2023 ('2023').

During the financial period 1 January 2024 to 31 December 2024, expenditure totalled £1,339,027 (2023: £803,622) and income was £1,185,503 (2023: £966,965). As income is over £1,000,000 the charity is required to have an audit.

The comparative figures for 2023 have been amended since the 2023 accounts were filed, please see note 4 for details.

Our financial goals are to maintain sufficient funds held in reserve to assure our continued existence under difficult financial situations (poor income years, and unusual economic times), while we continue to support funding for Science Schools, Post Graduate Courses, the Allan Drash Clinical Fellowship, Research Fellowship, Travel Grants, Hormone Research in Paediatrics, Guideline officer, Memberships, and special initiatives.

One of the challenges of holding our Annual Conferences in different locations around the world is the widely varying costs and benefits from them. The 2018 Conference in Hyderabad, India was a successful Conference in raising awareness across the wider region, but resulted in a negative balance, while the 45th Annual Conference in Boston, USA in 2019 resulted in a positive balance. The Annual Conferences in 2020 and 2021 were both virtual, with good attendance and they resulted in positive balances. The Annual Conference in 2023 took place in Rotterdam, Netherlands and was a very successful meeting and resulted in a positive balance. The Annual Conference in 2024 took place in Lisbon, Portugal and was a very successful meeting with the highest number of attendees in our history. The following years our conference will move to Montreal, Canada in 2025 and Rio de Janeiro, Brazil in 2026, with uncertainties in terms of financial success.

A crucial element of our charitable aims is to facilitate access to science and education, especially for young health professionals involved with diabetes across all countries of the world. To this end we support travel grants (scaled according to geographical location) and special travel grants (full payment of travel, registration and accommodation for members from the developing world). Starting from July 1, 2020, ISPAD has reduced membership and registration fees for members from Upper-middle-income countries as well as waived membership fees for Low-income countries.

Reserves Policy

Our policy is to maintain reserves of sufficient funds to provide ongoing support for at least one year of Charity activity. ISPAD currently aims to keep reserves of £700,000. The balance of total reserves at the year end was £1,270,862 (2023: £1,434,386) of which £958,509 (2023: £1,116,795) was free reserves, this compares with £1,185,503 of total income in the period ended 31 December 2024 (2023: £966,965), and £662,295 (2023: £486,413) was restricted. Conference income is very unpredictable and the current financial climate demands that we hold a slightly increased reserve. This is considered to be prudent also in light of the fact that the next two conferences will take place in Northern and Southern America and corporate sponsorship has become more challenging to obtain.

The comparative figures for 2023 have been amended since the 2023 accounts were filed, please see note 4 for details.

Investment Policy and Objectives

The overriding philosophy and policy is that the Charity will take only minimal risk in order to preserve funds. The objectives are to garner when possible, reasonable interest on held funds without placing reserves or day-to-day funds at risk.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Income:

During 2022, we again observed an increase in total membership numbers, mainly because the in-person conference in Abu Dhabi raised local interest and new members from the area. Our Annual Conferences in Rotterdam 2023 and Lisbon 2024 were very well attended and also affected our membership numbers. The Annual Conference in Lisbon 2024, resulted in a positive balance. This was both because of an increase in number of attendees and increase in sponsorship income, positively influenced by the realisation of our meeting in Europe.

ISPAD will continue to work hard in order to increase the numbers of members, both in specific regions as well as worldwide.

Regarding Corporate Membership and Sponsorship, which are extremely important sources of income for ISPAD, the situation is still uncertain. So far, all key sponsors have maintained their commitments. Still, we are aware that the situation for many of our Corporate collaborators are uncertain, and we should not take their support for granted for the upcoming years.

Expenses:

There are still, and will most likely always be, uncertainties with respects to the allocation and format of several of ISPAD core activities. This includes our science schools, both for physicians and healthcare providers, the ASPED-ISPAD-Academy, CDiC training, ADECA training and finally the Allan Drash fellowships. The restricted funding from different sponsors for these activities will depend on the activities' format (in-person or virtual). These activities are of course very important for ISPAD as society, and we have to be flexible, dynamic and pragmatic to maintain as many as them as well.

In summary, there are more risks and uncertainties than usual in the current situation. Nonetheless, the financial situation is very safe within the fiscal year 2024 due to headroom given by the level of reserves.

The Trustees undertake detailed planning and forecasting across the year. Due to this, the Trustees believe that the Charity's financial resources, strong reserves position and contingency planning is sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of these financial statements. There are no material uncertainties about the ability to continue and therefore the financial statements have been prepared on a going concern basis.

Looking ahead

ISPAD has increased engagement with patient advocacy and team membership groups during this reporting year, and has encouraged them to meet at our Annual Conferences and to publicise the work and mission of ISPAD. In the 2024, the Society celebrated its 50th anniversary in the annual meeting in Lisbon, Portugal, with the highest number of attendees ever. The next Annual Conferences will take place in Montreal, Canada in 2025 and in Rio de Janeiro, Brazil in 2026.

Due to the COVID-19 pandemic, the international conflicts and climate changes, the financial situation is still challenging and rules and regulations for support from industry have changed making it more difficult for ISPAD to receive corporate membership fees or specific grants. We are grateful for those who have been able to continue to support ISPAD. For this reason, ISPAD offers different levels to become a corporate member or sponsor, with different benefits. ISPAD, to enhance its relationship with companies, organizes a specific and strategic meeting (Corporate Advisory Board Meeting) annually with all companies during its Winter Meeting.

Since 2019, this meeting has been taking place adjacent to the ATTD (Advanced Technologies and Treatments in Diabetes) in order to enable maximum industry attendance. Furthermore the Executive Board Members meet with industry partners at the Summer Meeting (taking place at ADA - American Diabetes Association) and of course during the ISPAD Annual Conference in autumn every year. The invoiced year for corporate membership is now the calendar year (January to December). To strengthen the financial commitment with our corporate partners even more, we plan to offer three-year corporate memberships in the up-coming years.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Membership payments are becoming increasingly important. The number of lapsed members might be significantly reduced by improving the payment process and the possibilities to interact with other members. In order to improve payment of membership fees and to enhance the member experience and modernize its online presence, ISPAD has launched a new membership software and an upgraded website in 2024. After a decline in membership during COVID-19 Pandemic, we could now stabilize our Membership and work on slightly increasing the membership income in 2025.

We still anticipate that ISPAD will likely face global inflation in the upcoming fiscal years. We expect that some corporate members and sponsors may withdraw as their financial situation is uncertain. Although others may become new members, we may see a reduction in total corporate members and sponsorships. Therefore, maintaining reserves of sufficient funds are more important than ever for ISPAD.

We have also initiated a revised accounting system for invoicing to be performed by K.I.T. Group in conjunction with and approval by the ISPAD Treasurer. This system is designed to provide redundancy and avoid missing opportunities for ISPAD funding.

Charity Governance Code

ISPAD aims to address the seven principles of the Charity Governance Code:
<https://www.charitygovernancecode.org/en/front-page>

1. Organisational purpose: to facilitate the mission of ISPAD to improve the lives of children, adolescents and young adults with diabetes worldwide. To do this we provide forums, both written (guidelines, e-Learning) and face-to-face (scientific meetings, science schools for physicians and for allied healthcare professionals, and postgraduate courses), to physicians and healthcare professionals who provide care for young people with diabetes. We have three main pillars to achieve our mission: science, education and advocacy.

2. Leadership; the Trustees comprise an Executive Board and are advised by an Advisory Committee. We take collective responsibility for the Board's decisions. The roles of each Trustee are clearly identified (Winter Executive Meeting February 2020). Since 2017, the Executive Board now includes a Communications Director to facilitate effective communication with the membership and community.

3. Integrity; the Executive Board acts with integrity and is conscious of how it is perceived by the membership and the public. A corporate liaison officer was appointed in February 2018 to assist with communication and perception in the community, the "Diabetes Online Community" including consumer "bloggers". We facilitate their meetings at our Annual Conference and meet with them at meetings organized by the consumer organization Children With Diabetes (February 2020). Conflicts of interest are declared.

4. Decision-making, risk and control; the Board makes sure that operational plans and budgets are in line with the charity's purpose. The Board invested in forward planning by expenses for representatives to meet and teach in India (2016-2020), the country with the second largest number of children with diabetes, and in Africa (2019, 2020, 2022, 2023, 2024).

5. Board effectiveness; the Board acts as an effective team and encourages members of the Advisory Board to set up Special Interest Groups at the Annual Conference in October 2017 onwards. Trustees are reflective of their performance and discuss areas that can be strengthened.

6. Equality, Diversity and Inclusion; the Board encourages diversity in the membership of committees, and in special non-physician positions on the Advisory Board.

7. Openness and accountability; the Board communicates with the membership by the Annual General Meeting and by monthly newsletters sent by email. The President writes special messages since 2017 which can be sourced on the Society's website. The Annual Report is circulated to the Membership and is available to the Public.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Statement of Trustees' Responsibilities

The Trustees (who are also directors of the International Society for Paediatric and Adolescent Diabetes for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charitable Company and of the incoming resources and application of resources, including the income and expenditure, of the Charitable Company for that period. In preparing these financial statements, the Trustees are required to:


- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charitable Company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charitable Company's transactions, disclose with reasonable accuracy at any time the financial position of the Charitable Company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the Charity's constitution. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The report of the Trustees has been prepared in accordance with the special provisions relating to small companies subject to the small companies regime within part 15 of the Companies Act 2006.

Approved by the Board of Trustees of The International Society for Paediatric and Adolescent Diabetes on
31/10/2025 and signed on its behalf by:

Dr Sabine Hofer
Trustee



THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY FOR
PEDIATRIC AND ADOLESCENT DIABETES**

Opinion

We have audited the financial statements of The International Society for Pediatric and Adolescent Diabetes (the 'company') for the year ended 31 December 2024 which comprise the Statement of Comprehensive Income, the Balance Sheet, the Statement of Cash Flows, the Statement of Changes in Equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, except for the possible effects of the matter described in the basis for qualified opinion section of our report the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

We draw attention to note 2 in the financial statements, which indicates that within the next 12 months from the signing of the accounts that the charitable company will relocate out of the UK. As stated in note 2 these events or conditions, along with the other matters as set forth in note 2, indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Our evaluation of the trustee's assessment of the entity's ability to continue to adopt the going concern basis of accounting included reviewing the entities accounts line by line to ensure the appropriate accounting policies have been followed due to the charity no longer having a presence in the UK.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY FOR
PEDIATRIC AND ADOLESCENT DIABETES (CONTINUED)**

Other information

The other information comprises the information included in the Annual Report other than the financial statements and our Auditor's Report thereon. The Trustees are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

Except for the matter described in the basis for qualified opinion section of our report, in the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatement in the trustees report.

Arising solely from the limitation on the scope of our work relating to memberships and travel grants:

- We were unable to determine whether adequate accounting records have been kept

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made;

Responsibilities of trustees

As explained more fully in the Trustees' Responsibilities Statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY FOR
PEDIATRIC AND ADOLESCENT DIABETES (CONTINUED)**

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Identifying and testing journal entries and the overall accounting records, in particular those that were significant.
- Reviewing the financial statement disclosures and determining whether accounting policies have been appropriately applied.
- Testing key revenue lines, in particular restricted funds, for evidence of management bias.
- Reviewing documentation such as the company board minutes, for discussions of irregularities including fraud.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's Report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the Charity's trustees those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's and its trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY FOR
PEDIATRIC AND ADOLESCENT DIABETES (CONTINUED)**

**Philip Arch FCA FCCA FMAAT (Senior Statutory Auditor) for and on behalf of
Wilkes Tranter & Co Limited**

Chartered Accountants
Statutory Auditors

Brook House

Moss Grove

Kingsinford

DY6 9HS


Philip Arch (Oct 31, 2025 15:46:53 GMT)

Date: 31/10/2025

Wilkes Tranter & Co Limited are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2024

		Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 As restated £</i>
	Note				
Income from:					
Donations		-	-	-	47
Charitable activities:					
Membership income		112,071	-	112,071	105,698
Corporate sponsorship income		72,412	662,295	734,707	485,530
Corporate membership		140,806	-	140,806	161,136
Conference income		197,919	-	197,919	201,696
Other income: Royalties		-	-	-	12,858
Total income		523,208	662,295	1,185,503	966,965
Expenditure on:					
Charitable activities	5	681,232	667,795	1,349,027	803,622
Total expenditure		681,232	667,795	1,349,027	803,622
Net (expenditure)/income		(158,024)	(5,500)	(163,524)	163,343
Transfers between funds	15	(262)	262	-	-
Net movement in funds		(158,286)	(5,238)	(163,524)	163,343
Reconciliation of funds:					
Total funds brought forward		1,116,795	317,591	1,434,386	1,271,043
Net movement in funds		(158,286)	(5,238)	(163,524)	163,343
Total funds carried forward		958,509	312,353	1,270,862	1,434,386

The notes on pages 20 to 36 form part of these financial statements.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)
REGISTERED NUMBER: 06641016

BALANCE SHEET
AS AT 31 DECEMBER 2024

	Note	2024 £	2023 As restated £
Current assets			
Debtors	12	495,350	141,699
Cash at bank and in hand		1,742,738	1,832,702
		<u>2,238,088</u>	<u>1,974,401</u>
Current liabilities			
Creditors: amounts falling due within one year	13	(940,492)	(503,674)
Net current assets		<u>1,297,596</u>	<u>1,470,727</u>
Total assets less current liabilities		<u>1,297,596</u>	<u>1,470,727</u>
Creditors: amounts falling due after more than one year	14	(26,734)	(36,341)
Total net assets		<u><u>1,270,862</u></u>	<u><u>1,434,386</u></u>
Charity funds			
Restricted funds	15	312,353	317,591
Unrestricted funds	15	958,509	1,116,795
Total funds		<u><u>1,270,862</u></u>	<u><u>1,434,386</u></u>

The entity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the entity to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

However, an audit is required in accordance with section 144 of the Charities Act 2011.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)
REGISTERED NUMBER: 06641016

BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The financial statements were approved and authorised for issue by the Trustees on
31/10/2025 and signed on their behalf by:

Dr Sabine Hofer
Trustee

A handwritten signature in blue ink, appearing to read 'Hofer Sabine', is written over a faint yellow rectangular background.

The notes on pages 20 to 36 form part of these financial statements.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	2024 £	2023 <i>As restated</i> £
Cash flows from operating activities			
Net cash from operating activities	17	(89,964)	260,425
Change in cash and cash equivalents in the year		(89,964)	260,425
Cash and cash equivalents at the beginning of the year		1,832,702	1,572,277
Cash and cash equivalents at the end of the year	18	<u>1,742,738</u>	<u>1,832,702</u>

The notes on pages 20 to 36 form part of these financial statements

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. General information

The International Society for Pediatric and Adolescent Diabetes (ISPAD) is a charitable company, limited by guarantee, (registration number 06641016 England & Wales) and the Charity Commission (charity number 1126927). The registered office address is Harrison Clark Rickerbys Limited, Ellenborough House, Wellington Street, Cheltenham, Gloucestershire, GL50 1YD.

2. Accounting policies

2.1 Basis of preparation of financial statements

These financial statements present information about the Charity as an individual undertaking. The current period is for the year ended 31 December 2024 ('2024'). The prior period is for the year ending 31 December 2023 ('2023').

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006 and the Charities Act 2011.

The International Society for Pediatric and Adolescent Diabetes meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The Trustees have undertaken detailed planning and forecasting and continue to closely monitor persistent global uncertainties, including inflationary pressures and geopolitical instability. Although the Trustees observed a positive conference income in 2024, there are still uncertainties over future corporate income and income and costs associated with conferences and other educational programs involving travel and logistical expenses.

Despite these challenges, the Trustees believe that the Charity's financial resources, strong reserves position and contingency planning is sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of these financial statements, notwithstanding, there is material uncertainty in relation to the going concern of the charity as the charity plans to move out of the UK in either 2026 or 2027.

2.3 Income

Income is recognised in the financial statements when the Charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Membership income is recognised in line with the financial year. Membership income for future years is deferred.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.4 Expenditure

All expenditure is accounted for on an accruals basis. Support costs are apportioned to cost activities based on the estimated amount attributable to that cost in the year on the basis of the estimated time spent on that activity. The irrecoverable element of VAT is included with the item of expense to which it relates.

Charitable activities comprise all expenditure incurred directly relating to the objects of the Charity.

Grants are recognised when a constructive obligation arises that results in the payment being unavoidable.

Governance costs include the costs connected with the Charity's constitutional and statutory requirements.

Charitable activities are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

2.5 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Statement of Financial Activities.

The functional currencies of ISPAD are considered to be Euros and US Dollars because these are the currencies used by the members of the Society in the primary economic environment in which the charity operates, Europe and the rest of the world. The financial statements are presented in pounds sterling.

2.6 Taxation

As a registered Charity the entity is entitled to taxation exemptions on all its income and gains, properly applied for its charitable purposes.

2.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid.

2.8 Cash at bank and in hand

Cash is represented by cash in hand and deposits with financial institutions.

2.9 Creditors

Creditors are recognised once there is a legal or constructive obligation that commits the Charity to the obligation.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.10 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2.11 Fund accounting

Unrestricted funds expendable at the discretion of the Trustees in furtherance of objectives and administration of the Charity.

Restricted funds are to be used for specified purposes laid down by the donor. Expenditure for those purposes is charged to the restricted fund.

3. Critical accounting estimates and areas of judgement

Preparation of the financial statements requires management to make any significant estimates and judgements where necessary.

Critical accounting estimates and assumptions:

Impairment of debtors

The charity makes an estimate of the recoverable value of membership debtors. When assessing impairment management considers historical experience. See note 12 for the net carrying amount of debtors.

4. Prior year adjustment

A prior year adjustment was made for a the backdated registration of VAT. An adjustment was made to increase the VAT liability by £53,333 at 31 December 2023. £36,049 related to VAT incurred up to 31 December 2022 and was therefore posted as an exceptional expense to the profit and loss. £17,284 related to VAT incurred during the year ended 31 December 2023 and has therefore been recognised in the Statement of Financial Activities comparatives.

Reserves carried forward in the 2023 filed accounts totalled £1,487,719. Following the prior year adjustment of £53,323 the restated comparatives in this report total £1,434,386.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

5. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Membership costs	482,401	-	482,401
Conference costs	108,364	-	108,364
Grants and Prizes (note 7)	60,343	231,461	291,804
ISPAD Science School for Physicians	-	66,326	66,326
ISPAD Science School for Healthcare Professionals	-	24,763	24,763
PETCA/PETCWA Research and projects	-	12,575	12,575
Allan Drash Fellowship	-	51,652	51,652
FID-ISPAD Research Grant	-	38,331	38,331
ISPAD Guidelines	30,124	-	30,124
ISPAD-JDRF Fellowship	-	175,291	175,291
Other	-	67,396	67,396
Total 2024	681,232	667,795	1,349,027

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

5. Analysis of expenditure on charitable activities (continued)

Summary by fund type (continued)

	<i>Unrestricted funds 2023 As restated £</i>	<i>Restricted funds 2023 As restated £</i>	<i>Total 2023 As restated £</i>
Membership costs	344,088	4,308	348,396
Conference costs	75,361	-	75,361
Grants and Prizes (note 7)	42,070	58,900	100,970
ISPAD Science School for Physicians	-	79,052	79,052
ISPAD Science School for Healthcare Professionals	-	27,030	27,030
PETCA/PETCWA Research and projects	504	13,226	13,730
Allan Drash Fellowship	-	58,880	58,880
Discovery of Insulin (Children's Book)	-	291	291
FID-ISPAD Research Grant	-	16,372	16,372
ISPAD Guidelines	2,697	-	2,697
ISPAD-JDRF Fellowship	-	39,296	39,296
Other	1,985	39,562	41,547
<i>Total 2023</i>	<u>466,705</u>	<u>336,917</u>	<u>803,622</u>

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6. Analysis of expenditure by activities

	Activities undertaken directly 2024 £	Support costs 2024 £	Total funds 2024 £
Membership costs	70,781	411,620	482,401
Conference costs	96,129	12,235	108,364
Grants and Prizes (note 7)	262,624	29,180	291,804
ISPAD Science School for Physicians	64,999	1,327	66,326
ISPAD Science School for Healthcare Professionals	22,039	2,724	24,763
CDIC Grant	12,512	63	12,575
Allan Drash Fellowship	42,355	9,297	51,652
FID-ISPAD Research Grant	38,139	192	38,331
ISPAD Guidelines	29,823	301	30,124
ISPAD-JDRF Fellowship	159,829	15,462	175,291
Other	67,396	-	67,396
Total 2024	866,626	482,401	1,349,027

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

6. Analysis of expenditure by activities (continued)

	<i>Activities undertaken directly 2023 As restated £</i>	<i>Support costs 2023 As restated £</i>	<i>Total funds 2023 As restated £</i>
Membership costs	37,679	310,717	348,396
Conference costs	67,825	7,536	75,361
Grants and Prizes (note 7)	90,873	10,097	100,970
ISPAD Science School for Physicians	77,471	1,581	79,052
ISPAD Science School for Healthcare Professionals	24,057	2,973	27,030
CDIC Grant	13,661	69	13,730
Allan Drash Fellowship	48,282	10,598	58,880
Discovery of Insulin (Children's Book)	291	-	291
FID-ISPAD Research Grant	16,290	82	16,372
ISPAD Guidelines	2,670	27	2,697
ISPAD-JDRF Fellowship	34,580	4,716	39,296
ADECA/Other	41,547	-	41,547
<i>Total 2023</i>	<u>455,226</u>	<u>348,396</u>	<u>803,622</u>

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

7. Grants and prizes

	2024	<i>2023</i>
	£	<i>As restated</i>
		£
Special Travel Grants	6,207	12,424
Young Investigator Award	-	436
ISPAD Prize for Innovation	-	1,853
Lestradet Award	-	1,348
Standard Travel Grants	28,725	15,683
Hero Award	-	1,053
Prize Winners	12,311	5,496
Other Travel Grants	244,561	62,677
	291,804	100,970

Details of the winners of ISPAD prizes and fellowships is available at;

www.ispad.org/?page=ISPADPrizeWinners.

All grants, prizes and fellowships are to individuals. During the year grants were paid to 112 individuals (2023: 57).

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

8. Support costs

	2024	<i>2023</i>
	£	<i>As restated</i>
		£
Insurance	1,390	1,096
Bank charges	7,109	3,584
Credit card fees	4,370	4,363
Membership dues	12,045	4,853
Management charge	276,249	214,834
Advertising and promotion	73,741	17,171
Research and education	-	1,751
Journal costs	14,768	-
Governance costs		
Accountancy fees	13,950	10,586
Audit fees	10,000	-
Legal fees	3,786	399
Exchange loss/ (gain)	44,560	51,341
Webinars	3,433	2,369
VAT penalty provision	17,000	-
Exceptional expenses	-	36,049
	482,401	348,396

Exchange rate gain/loss

This is not a trading '(gain)/loss' as ISPAD does not trade currencies. It is an 'accounting adjustment' and represents the difference in value of non-sterling balances at the year end in comparison to the start of the year where different exchange rates were in effect. As an example a balance of \$10,000 at the start of the financial year might be worth £7,600 (at a USD/GBP exchange rate of 0.76) and at the end of the year that might have changed to £7,870 (at a USD/GBP exchange rate of 0.787). This would result in an apparent gain of £270 while in fact there had been no change to the \$10,000 held.

The foreign exchange loss is included in support costs and was £70,952 (2023: £119,812 loss).

Exceptional expenses

Included in the above costs in 2023 are exceptional items totaling £36,049 which is a backdated amendment relating to VAT that should have been incurred up to 31 December 2022.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

9. Auditor's remuneration

	2024	<i>2023</i>
	£	<i>As restated</i>
		£
Fees payable to the Charity's auditor for the audit of the Charity's annual accounts (2023: independent examination)	10,000	7,000
Fees payable to the Charity's auditor in respect of:		
All taxation advisory services not included above	7,000	-
All assurance services not included above	6,950	3,000
	<u>13,950</u>	<u>10,000</u>

10. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the period ended 31 December 2024, expenses totalling £22,870 were reimbursed or paid directly to 5 Trustees (2023 - £6085 to 4 Trustees). Expenses related to travel, accommodation and subsistence.

11. Key management remuneration

The Trustees and Executive Board are the key management of the charity. The key management does not receive any remuneration for their services.

12. Debtors

	2024	<i>2023</i>
	£	<i>As restated</i>
		£
Due within one year		
Trade debtors	444,429	48,841
Other debtors	-	91,225
Prepayments and accrued income	50,921	1,633
	<u>495,350</u>	<u>141,699</u>

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

13. Creditors: Amounts falling due within one year

	2024	<i>2023</i> <i>As restated</i>
	£	£
Trade creditors	508,894	183,830
Other taxation and social security	85,819	53,333
Accruals and deferred income	345,779	266,511
	940,492	503,674
	£	£
	2024	<i>2023</i> <i>As restated</i>
	£	£
Deferred income at 1 January 2024	125,620	136,687
Resources deferred during the year	115,849	114,539
Amounts released from previous periods	(117,336)	(125,606)
	124,133	125,620

Deferred income relates to membership subscriptions, corporate membership for future years and the JDRF Fellowship.

14. Creditors: Amounts falling due after more than one year

	2024	<i>2023</i> <i>As restated</i>
	£	£
Accruals and deferred income	26,734	36,341

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

15. Statement of funds

Statement of funds - current year

	Balance at 1 January 2024 As restated £	Income £	Expenditure £	Transfers in/out £	Balance at 31 December 2024 £
Unrestricted funds					
General Funds - all funds	1,116,795	523,208	(681,232)	(262)	958,509
Restricted funds					
ISPAD SSHP	9,677	26,836	(24,763)	-	11,750
Alan Drash Fellowship	145	57,497	(51,652)	-	5,990
Innovation Prize	17,277	6,376	(716)	-	22,937
Wedcasting Sponsorship	3,254	-	(3,516)	262	-
Young Investigator's Award	16,719	6,098	-	-	22,817
Lestradet Award	20,706	6,376	(2,463)	-	24,619
Discovery of Insulin	8,960	-	-	-	8,960
ASPED-ISPAD Lilly Diabetes Postgraduate Course	8,809	-	-	-	8,809
JDRF Fellowship	57,739	183,989	(175,291)	-	66,437
Novo Nordisk/Lily SSP	16,207	61,330	(66,327)	-	11,210
Lily Prize for Achievement	9,618	6,556	(4,013)	-	12,161
Hero Award	6,492	6,325	(1,602)	-	11,215
FID- ISPAD Grant	4	41,112	(38,331)	-	2,785
Changing Diabetes in Children	141,984	157,959	(244,832)	-	55,111
ADECA	-	101,841	(54,289)	-	47,552
	317,591	662,295	(667,795)	262	312,353
Total of funds	1,434,386	1,185,503	(1,349,027)	-	1,270,862

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

15. Statement of funds (continued)

Statement of funds - prior period

	<i>Balance at 1 January 2023 As restated £</i>	<i>Income As restated £</i>	<i>Expenditure As restated £</i>	<i>Transfers in/out As restated £</i>	<i>Balance at 31 December 2023 As restated £</i>
Unrestricted funds					
General Funds - all funds	1,135,179	480,552	(466,705)	(32,231)	1,116,795
Restricted funds					
ISPAD SSHP	7,549	27,458	(25,330)	-	9,677
Alan Drash Fellowship	-	59,025	(58,880)	-	145
Innovation Prize	18,078	-	(801)	-	17,277
Wedcasting Sponsorship	3,254	-	-	-	3,254
Young Investigator's Award	10,707	6,012	-	-	16,719
Lestradet Award	14,992	6,009	(295)	-	20,706
Discovery of Insulin	9,251	-	(291)	-	8,960
ASPED-ISPAD Lilly Diabetes Postgraduate Course	8,809	-	-	-	8,809
JDRF Fellowship	18,585	78,450	(39,296)	-	57,739
Novo Nordisk/Lily SSP	32,048	63,211	(79,052)	-	16,207
Lily Prize for Achievement	7,717	6,203	(4,302)	-	9,618
Hero Award	399	6,093	-	-	6,492
ADECA	-	-	(32,231)	32,231	-
FID- ISPAD Grant	4	16,372	(16,372)	-	4
Changing Diabetes in Children	4,471	217,580	(80,067)	-	141,984
	135,864	486,413	(336,917)	32,231	317,591
Total of funds	1,271,043	966,965	(803,622)	-	1,434,386

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

15. Statement of Funds (continued)

ISPAD Science School for Healthcare Professionals

This is funds used to support the Science School for Healthcare Professionals which is a three day course in the field of childhood diabetes to learn about research development, statistics and grant writing.

Allan Drash Fellowship

Allan Drash was one of ISPAD's founding members and in his memory ISPAD offers a 6 week clinical fellowship. Applications are invited from members below 45 years of age. A report must be submitted to the ISPAD Steering Committee within 1 year after fellowship.

The ISPAD Prize for Innovation in Pediatric Diabetes Care

Sponsored by NovoNordisk within their DAWN™ Youth Initiative, this prize is for any professional, group or individual who has made a significant (non-commercial) innovation in pediatric diabetes care. DAWN™ Youth is a global programme to guide the wider diabetes community to address the unmet needs of young people with diabetes, their families, peers and healthcare professionals. This prize puts the focus on diabetes in childhood by recognising innovations to improve health and quality of care for children and young people.

Discovery of Insulin

100 years of the discovery of insulin was celebrated in 2021 and 2022. To celebrate, ISPAD prepared various communications across its website and social media. A "comic book" was devised for young people (Insulin: The Incredible Discovery), describing the discovery of Insulin (with drawings by Rebecca Redmond and story by Jade Bryne). The comic book was disseminated at several meetings/events last year.

Webcasting

The webcasting fund was initially created for costs related to ISPAD's first webcasting Platform in 2014 (Annual Conference in Toronto). Since 2015, ISPAD has a new Resource Platform, for which the funding and related costs are now managed as part of the conference budget, managed by K.I.T Group, in close collaboration with ISPAD.

The ISPAD-ASPED Lilly diabetes postgraduate course

The ISPAD/ASPED/Lilly diabetes postgraduate course (previously described as the Post Grad Course Arabian) is an initiative from ASPED in collaboration with ISPAD. The aim of the course is to empower and update physicians practicing in the Arab countries who are involved in the care of young people with diabetes and is intended to be a platform to share expertise, research and development in the field of diabetes.

ISPAD JDRF Fellowship

JDRF has signed a MoU with ISPAD with the aim to award each year for three years starting in 2017, four grants of \$25,000 to award the four best research projects submitted by young researchers, who are ISPAD members, aged 40 or below. The grant can be spent in a hosting center of excellence but also at their own center.

Novo Nordisk/Lilly SSP 2018

These are funds to support the Science School for Physicians.

The remaining restricted funds are donations or grants which must be awarded to individuals.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

15. Statement of Funds (continued)

Hero Award

This award identifies and honours non-clinicians from around the world who have developed projects with a broad impact, thus contributing to improving and transforming the lives of many young people with diabetes. More information can be found here: <https://www.ispad.org/page/ISPADHEROAWARD>.

ISPAD Guidelines 2022

ISPAD's Clinical Practice consensus guidelines are the only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes worldwide. Authors include experts from across the globe and a chapter on limited care for developing healthcare systems has also been developed. A great amount of work is involved in reviewing these chapters every four years. In order to ensure consistency and solid research across all chapters, ISPAD paid for the support of a freelancing project officer to help with his specific assignment. The final set of guidelines for 2022 are available here: <https://www.ispad.org/page/ISPADGuidelines2022>

ADECA

The Allied Healthcare Professionals Pediatric Diabetes Educator Course for Africa (ADECA) is a diabetes education and management course that targets qualified nurses and allied health professionals working in Africa and trains them to become pediatric diabetes educators. ADECA is a hybrid course which includes a combination of E-learning and in person (face-to-face) modules.

FID-ISPAD Grant

This grant is for ISPAD members, preferably below the age of 40. The scope of the research grant is related to the identification of a cure for type 1 diabetes, meaning a procedure or therapy that can ensure the normalization and maintenance over time of a normal glucose balance in the absence of external insulin administration. This category includes projects on pathogenesis, prediction, prevention, beta-cell replacement, organ and cell transplantation, tissue regeneration and stem cells, gene therapy.

Explicitly excluded from funding is research on insulin, drugs, glucose sensor technologies, or insulin infusers, which pertain to pharmaceutical and biotechnology companies. Also excluded is research related to complications of diabetes and research related to type 2 diabetes or forms of diabetes other than type 1 diabetes.

The FID-ISPAD Research Grant program is only open to applicants from non-profit institutions or groups of such institutions. One recipient per year is selected, and receives a funding amount of EUR 25,000 for their research.

Changing Diabetes in Children

Changing Diabetes in Children partnered with ISPAD in 2019-2022 with developing training material and workshops in Cambodia to raise awareness about T1D. The funding came from ISPAD and the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ). This fund/activity has therefore been renamed to ISPAD-CDiC- T1D Training (Cambodia).

Changing Diabetes in Children (CDiC)

There is a very recent agreement (2023) with CDiC, which will be relevant for the year end 2023 accounts. Changing Diabetes® in Children is a public-private partnership established in 2009. The partnership provides comprehensive care for children and young people living with type 1 diabetes in low- and middle-income countries. This includes free life-saving medicine and supplies for persons up to 25 years of age.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

16. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
Current assets	1,712,555	525,533	2,238,088
Creditors due within one year	(727,312)	(213,180)	(940,492)
Creditors due in more than one year	(26,734)	-	(26,734)
Total	958,509	312,353	1,270,862

Analysis of net assets between funds - prior period

	<i>Unrestricted funds 2023 As restated £</i>	<i>Restricted funds 2023 As restated £</i>	<i>Total funds 2023 As restated £</i>
Current assets	1,491,118	483,283	1,974,401
Creditors due within one year	(337,982)	(165,692)	(503,674)
Creditors due in more than one year	(36,341)	-	(36,341)
Total	1,116,795	317,591	1,434,386

17. Reconciliation of net movement in funds to net cash flow from operating activities

	2024 £	2023 As restated £
Net income/expenditure for the period (as per Statement of Financial Activities)	(163,524)	163,343
Adjustments for:		
(Increase)/ decrease in debtors	(353,650)	144,139
Increase in creditors	427,210	(100,390)
Net cash provided by/(used in) operating activities	(89,964)	207,092

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

18. Analysis of cash and cash equivalents

	2024	<i>2023</i> <i>As restated</i>
	£	£
Cash in hand	1,742,738	<i>1,832,702</i>
Total cash and cash equivalents	<u>1,742,738</u>	<i><u>1,832,702</u></i>

19. Analysis of changes in net debt

	At 1 January 2024	Cash flows	At 31 December 2024
	£	£	£
Cash at bank and in hand	1,832,702	(89,964)	1,742,738
	<u>1,832,702</u>	<u>(89,964)</u>	<u>1,742,738</u>

20. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 December 2024.